RT Journal Article
SR Electronic
T1 Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel – A Final Analysis of the Prosty II Trial
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 6915
OP 6921
DO 10.21873/anticanres.14715
VO 40
IS 12
A1 KELLOKUMPU-LEHTINEN, PIRKKO-LIISA
A1 MARTTILA, TIMO
A1 JEKUNEN, ANTTI
A1 HERVONEN, PETTERI
A1 KLINTRUP, KATARIINA
A1 KATAJA, VESA
A1 UTRIAINEN, TAPIO
A1 LUUKKAA, MARJAANA
A1 LESKINEN, MARKKU
A1 PULKKANEN, KALEVI
A1 KAUTIO, ANNA-LIISA
A1 HUTTUNEN, TEPPO
YR 2020
UL http://ar.iiarjournals.org/content/40/12/6915.abstract
AB Background/Aim: Our phase III trial showed that biweekly docetaxel (D) is better tolerated than triweekly D in metastatic castration-resistant prostate cancer (mCRPC). The safety of biweekly cabazitaxel (CBZ) post-docetaxel was studied in mCRPC. Patients and Methods: Altogether, 60 patients received CBZ 16 mg/m2 i.v. on day 1 and day 14 of a 4-week cycle. The mean serum PSA levels were 305 ng/ml, and the mean age 67 years. The primary endpoint was safety according to CTCAEv4.0. Results: A total of 255 4-week cycles of CBZ were administered. The most common grade 3/4 adverse events were neutropenia (16.7%), pain (13.3%), fatigue (10.0%), anemia (5.0%) and non-neutropenic infection (10.0%). PSA responses occurred in 10 patients (16.7%). Clinical benefit rate was 38.3% and median survival 10 months. Conclusion: Biweekly CBZ is a well-tolerated treatment resulting in meaningful benefits for heavily pretreated mCRPC patients.